TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03763266

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 day low residue diet
Description: Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
Study: NCT03607786

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Inferior Vena Caval Perfusion
Description: Retrograde Inferior Vena Caval Perfusion is achieved by tethering the inferior vena cava with a band around the cannula and by clamping the distal end of the inferior vena cava drainage tube, which allowed a pump to drive oxygenated blood into the inferior vena cava. Pump pressure is maintained at 20-30 mmHg, and blood flow is maintained at 8-12 mL/min/kg. The aim of RIVP is to maintain the lower body perfusion during circulation arrest, and reduce the ischemia-associated vital organ injury.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Select antegrade cerebral perfusion
Description: Antegrade cerebral perfusion is achieved using a 12 F cannula inserted into the brachiocephalic artery or right axillary artery. The antegrade perfusion flow rate is maintained at 6-12 mL/min/kg
Study: NCT04090359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Mobility Implant
Description: Patients in this intervention will receive a dual mobility implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional, single-bearing implant
Description: Patients in this intervention will receive a conventional, single-bearing implant
Study: NCT01065766

Intervention type: DRUG
Intervention: Sitagliptin/metformin
Description: Sitagliptin/metformin 50/500 mg, 50/850 mg, or 50/1000 mg tablet administered twice daily with meals.
Study: NCT02057666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: A patient initially received a 0.25 mg/day dose which was then titrated through 0.5 mg/day (from Day 15) to a maximum of 1 mg/day (from Day 29). If tolerability issues arose at 0.5 or 1 mg/day, patients had their dose reduced to 0.25 or 0.5 mg/day, respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules were identical to tasquinimod capsules in appearance and excipients but excluded the active compound (tasquinimod).
Study: NCT02520154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01749735

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: Sham transcranial direct current stimulation will be used while the participant focuses on repetitive tasks using the Armeo device that incorporate multidirectional reaching, grasp and release action of the hand of the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo training
Description: Upper extremity training with the use of a weight support device and virtual reality.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Armeo training
Description: Upper extremity training with the use of a weight support device and virtual reality.
Study: NCT01221051

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: active management of the third stage of labor
Description: early cord clamping, administration of oxytocin 10 IU, controlled cord traction, uterine massage after placenta expulsion

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: expectant management of the third stage of labor
Description: early cord clamping, administer saline solution 2 mL i.v,wait for signs of placenta detachment, encourage the woman to push ot placenta by her own effort, uterine massage after placenta expulsion
Study: NCT01645280

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + methotrexate (MTX) (Group 1)
Description: Placebo: form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab + MTX (Group 2)
Description: Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab + MTX (Group 3)
Description: Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 12 weeks (Weeks 16 and 28) + MTX (pre-study dose)
Study: NCT02330809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily extra water intake
Description: Amount of extra daily water intake to consume

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily extra water intake
Description: Amount of extra daily water intake to consume

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of daily extra water intake
Description: Intervention-A: Timing of daily extra water intake specified Intervention-B: at any time during 24 hour period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of daily extra water intake
Description: Intervention-A: Timing of daily extra water intake specified Intervention-B: at any time during 24 hour period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of daily extra water intake
Description: Intervention-A: Timing of daily extra water intake specified Intervention-B: at any time during 24 hour period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of daily extra water intake
Description: Intervention-A: Timing of daily extra water intake specified Intervention-B: at any time during 24 hour period
Study: NCT00579436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acid
Description: 4g of omega-3 fatty acid daily by mouth for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 inert capsules daily by mouth for 12 weeks.
Study: NCT04679545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: A water-soluble sublingual tablet containing 20 mg of CBD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inactive compound.
Study: NCT02312882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib 5 mg tablet taken by mouth twice a day.
Study: NCT01255787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablets
Study: NCT00018616

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MEMS caps
Study: NCT01645280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959 + MTX (Group 4)
Description: CNTO 1959: type = exact number, unit = mg, number = 200, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959 + MTX (Group 5)
Description: CNTO 1959: type = exact number, unit = mg, number = 50, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28)+ MTX (pre-study dose)
Study: NCT01930409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Support and Coaching
Description: The participants will receive up to 5 telephone calls of 30-45 minutes each after hospital discharge to provide support and education for the transition from acute to community care. The first call will be made within 48-72 hours of hospital discharge and will have the following elements:~* Health Status~* Medication Management~* Activity/Exercise Prescription and Goal-Setting~* Falls Prevention~* Clarification of Appointments~* Coordination of Post-Discharge Home Services~* What To Do If a Problem Arises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Only
Description: An educational toolkit will be provided, with materials to self manage at home after hospital discharge following a fall related hip fracture

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Only
Description: An educational toolkit will be provided, with materials to self manage at home after hospital discharge following a fall related hip fracture
Study: NCT01512524

Intervention type: OTHER
Group type: OTHER
Intervention: MRI scan and endocrinology analysis
Description: Endocrinology analysis including statique and dynamic exams, neuropsychologic evaluations and IRM scan.
Study: NCT02157272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Rivaroxaban
Description: The investigated drug is Rivaroxaban 20mg, a film coated tablet, which is a highly selective direct factor Xa inhibitor. It should be administered orally, every day at any time (always the same), with food. The treatment should be performed for all the treatment period.
Study: NCT02642471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no systematic pelvic lymphadenectomy
Description: systematic pelvic lymphadenectomy is omitted in surgical treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no systematic pelvic lymphadenectomy
Description: systematic pelvic lymphadenectomy is omitted in surgical treatment
Study: NCT04134845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dantrolene/Ryanodex
Description: muscle relaxant
Study: NCT03500094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Migalastat HCl 150 mg
Description: migalastat HCl 150 mg capsule
Study: NCT04428645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DailyDose Decision Support
Description: DailyDose provides on-demand, real-time dosing recommendations for insulin meal boluses and basal insulin doses as well as the option to receive recommendations for meals and exercise. DailyDose is an information system comprised of (1) a smart phone app that both collects continuous glucose measurement (CGM) data, insulin data, and fitness data and presents suggestions back to the user, (2) a cloud based information system that stores the raw data and relays suggestions to the user, (3) a glucoregulatory model, automatically personalized for each user, that resides on a cloud server and is fit with the user's individual glucose data, and (4) an adaptive agent that provides insulin dosing options and suggestions as well as meal and exercise recommendations to the user based on the subject's own outcomes and simulations done on the glucoregulatory model.
Study: NCT02372006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Study: NCT04134845

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Controlled placebo of saline administered Intravenous; 1 mg/kg IV over 3 minutes, one time dose
Study: NCT03502733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study: NCT03789110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is called an anti- PD-1 or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is called an anti-CTLA-4 and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
Study: NCT04225364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Participants will receive camrelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin-bound)
Description: Paclitaxel for injection (albumin-bound): 260mg/m2(in total), ivgtt d1, d8, q3w，for 2 cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2(in total), ivgtt d1-d3, q3w, for 2 cycles
Study: NCT03097198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plum-blossom Needle
Description: * acupoint selection: Zhengguang 1, Zhengguang 2, GB20, GV14, LI4.~* plum-blossom needle manipulation methods: After the skin has been wiped with 75 % alcohol, plum-blossom needles will be tapped perpendicularly on the skin at the selected acupoints with wrist force and then lifted immediately. Each point will be tapped repeatedly for 20 to 50 times and both sides of cervical vertebra and temporal region, Suprao-infraorbital margin will be tapped repeatedly. Acupuncturists should tap the points gently to make patients feel only a little pain and stop when the skin gets flushed but is not bleeding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plum-blossom Needle
Description: * acupoint selection: Zhengguang 1, Zhengguang 2, GB20, GV14, LI4.~* plum-blossom needle manipulation methods: After the skin has been wiped with 75 % alcohol, plum-blossom needles will be tapped perpendicularly on the skin at the selected acupoints with wrist force and then lifted immediately. Each point will be tapped repeatedly for 20 to 50 times and both sides of cervical vertebra and temporal region, Suprao-infraorbital margin will be tapped repeatedly. Acupuncturists should tap the points gently to make patients feel only a little pain and stop when the skin gets flushed but is not bleeding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropicamide Eye Drops
Description: Instill one drop in both eyes every night before bed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropicamide Eye Drops
Description: Instill one drop in both eyes every night before bed.
Study: NCT03416673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peCTG+CAF
Description: A connective tissue graft will be reshaped to have extensions mimicking the papillae to augment the inter-dental papillae recessed
Study: NCT03502733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT03416673

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTG+CAF
Description: A connective tissue graft harvested from the palate will be sutured to the gingival recession site and covered with a coronally advanced flap
Study: NCT03502733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV
Study: NCT04917991

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil-enriched chocolate spread
Description: the intervention consists in the administration of 100g Extra Virgin Olive Oil-enriched chocolate spread each day for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Palm Oil-enriched chocolate spread
Description: the intervention consists in the administration of 100g Palm Oil-enriched chocolate spread each day for 14 days.
Study: NCT03843294

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAA-T cells
Description: The patient will receive two TAA-T cell infusions given 2 weeks apart. TAA-T cell dose: 2 x 107 cells/m2.per infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab: For patients \<18 years, 3 mg/kg/dose (maximum 240mg/dose) every 2 weeks. For adult patients ≥18 years, a dose of 240mg every 2 weeks or 480mg every 4 weeks
Study: NCT03502733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT03028792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Modification Program
Description: Each trial begins with a fixation cross at the center of the computer screen for 500 ms. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threat material. In this case, the probe always replaces the neutral stimuli. Thus, although there will be no specific instruction to direct attention away from the threat stimuli, on all trials, the position of the neutral stimulus will indicate the position of the probe.
Study: NCT03028792

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention Control Condition
Description: Each trial begins with a fixation cross presented in the center of the computer screen. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threat material. In this case, the probe randomly replaces the threat or neutral stimulus.
Study: NCT02157272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Rivaroxaban
Description: The investigated drug is Rivaroxaban 20mg, a film coated tablet, which is a highly selective direct factor Xa inhibitor. It should be administered orally, every day at any time (always the same), with food. The treatment should be performed for all the treatment period.
Study: NCT03029403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given intravenously in clinic, at 200 mg, on Day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given intravenously in clinic, at 200 mg, on Day 1 of every 21-day cycle.
Study: NCT03502733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03114072

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue-blocking glasses
Description: Wear the BB-glasses from three hours before bedtime, and if needed to turn on the light, also during the night.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light grey control glasses
Description: Wear the light grey glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
Study: NCT04340843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Given IV
Study: NCT03029403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given intravenously in clinic, at 200 mg, on Day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given intravenously in clinic, at 200 mg, on Day 1 of every 21-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: Given by injection under the skin of the upper thigh in clinic. Participants will receive one priming dose of 0.25 mL of DPX-Survivac on Cycle 1 Day 1. After about 6 weeks, participants will receive an additional boosting dose of 0.25 or 0.5 mL DPX-Survivac.
Study: NCT05652140

Intervention type: OTHER
Intervention: Data collections
Description: Data collections of cognitive function, neuroelectrical activities, ApoE genotype, and physical fitness.

Intervention type: OTHER
Intervention: Data collections
Description: Data collections of cognitive function, neuroelectrical activities, ApoE genotype, and physical fitness.
Study: NCT04340843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT04381377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azoximer bromide
Description: Investigational medicinal product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03326921

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00829478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid for Atrial Fibrillation
Description: Single contact educational session

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care